Sefik, Esen http://orcid.org/0000-0002-6807-3498
Israelow, Benjamin http://orcid.org/0000-0002-1308-8246
Mirza, Haris
Zhao, Jun
Qu, Rihao
Kaffe, Eleanna
Song, Eric http://orcid.org/0000-0001-5448-5865
Halene, Stephanie http://orcid.org/0000-0002-2737-9810
Meffre, Eric
Kluger, Yuval http://orcid.org/0000-0002-3035-071X
Nussenzweig, Michel http://orcid.org/0000-0003-0592-8564
Wilen, Craig B. http://orcid.org/0000-0003-2495-9403
Iwasaki, Akiko http://orcid.org/0000-0002-7824-9856
Flavell, Richard A. http://orcid.org/0000-0003-4461-0778
Funding for this research was provided by:
Howard Hughes Medical Institute
Damon Runyon Cancer Research Foundation (DRG-2316-18)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (2T32AI007517, AI061093, AI118855, K08AI128043, R01AI157488)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (F30CA239444, U01CA260507, CA016359)
https://www.mercatus.org/emergent-ventures
G. Harold and Leila Y. Mathers Foundation
G. Harold and Leila Y. Mathers Foundation
Burroughs Wellcome Fund
Robert E. Leet and Clara Guthrie Patterson Trust
G. Harold and Leila Y. Mathers Foundation
https://www.mercatus.org/emergent-ventures http://www.ludwick.org/
G. Harold and Leila Y. Mathers Foundation
Bill and Melinda Gates Foundation
Article History
Received: 26 February 2021
Accepted: 5 November 2021
First Online: 17 December 2021
Competing interests
: R.A.F. is an advisor to GlaxoSmithKline, Zai Lab and Ventus Therapeutics.
Free to read: This content has been made available to all.